Home

Download

Statistics

Examples

Help

Contact

	Fusion Gene Summary
	Fusion Gene ORF analysis
	Fusion Genomic Features
	Fusion Protein Features
	Fusion Gene Sequence
	Fusion Gene PPI analysis
	Related Drugs
	Related Diseases

Fusion gene:PCCA-TM9SF2 (FusionGDB2 ID:63163)

Fusion Gene Summary for PCCA-TM9SF2

Fusion gene summary

Fusion gene information	Fusion gene name: PCCA-TM9SF2
	Fusion gene ID: 63163
		Hgene	Tgene
	Gene symbol	PCCA	TM9SF2
	Gene ID	5095	9375
	Gene name	propionyl-CoA carboxylase subunit alpha	transmembrane 9 superfamily member 2
	Synonyms	-	P76
	Cytomap	13q32.3	13q32.3
	Type of gene	protein-coding	protein-coding
	Description	propionyl-CoA carboxylase alpha chain, mitochondrialPCCase alpha subunitpccA complementation grouppropanoyl-CoA:carbon dioxide ligase alpha subunitpropionyl CoA carboxylase, alpha polypeptidepropionyl Coenzyme A carboxylase, alpha polypeptidepropion	transmembrane 9 superfamily member 276 kDa membrane proteindinucleotide oxidase disulfide thiol exchanger 3 superfamily member 2epididymis secretory sperm binding proteintransmembrane protein 9 superfamily member 2
	Modification date	20200313	20200313
	UniProtAcc	.	.
	Ensembl transtripts involved in fusion gene	ENST00000485946, ENST00000376279, ENST00000376285, ENST00000376286,	ENST00000376387, ENST00000463709,
Fusion gene scores	* DoF score	20 X 16 X 12=3840	9 X 8 X 3=216
	# samples	25	9
	** MAII score	log2(25/3840*10)=-3.94110631094643 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(9/216*10)=-1.26303440583379 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Context	PubMed: PCCA [Title/Abstract] AND TM9SF2 [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint	PCCA(100809594)-TM9SF2(100169867), # samples:1
Anticipated loss of major functional domain due to fusion event.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner

Gene

GO ID

GO term

PubMed ID

Fusion gene breakpoints across PCCA (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across TM9SF2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene information from two resources (ChiTars 5.0 and ChimerDB 4.0)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Disease	Sample	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
ChimerDB4	Non-Cancer	203N	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+

Top

Fusion Gene ORF analysis for PCCA-TM9SF2

Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

ORF	Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand
3UTR-3CDS	ENST00000485946	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
3UTR-3UTR	ENST00000485946	ENST00000463709	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
5CDS-3UTR	ENST00000376279	ENST00000463709	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
5CDS-3UTR	ENST00000376285	ENST00000463709	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
5CDS-3UTR	ENST00000376286	ENST00000463709	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
In-frame	ENST00000376279	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
In-frame	ENST00000376285	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+
In-frame	ENST00000376286	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+

ORFfinder result based on the fusion transcript sequence of in-frame fusion genes.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000376279

PCCA

chr13

100809594

ENST00000376387

TM9SF2

chr13

100169867

3643

574

2394

776

ENST00000376286

PCCA

chr13

100809594

ENST00000376387

TM9SF2

chr13

100169867

3565

496

2316

750

ENST00000376285

PCCA

chr13

100809594

ENST00000376387

TM9SF2

chr13

100169867

3575

506

2326

762

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000376279	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+	0.000400072	0.9996
ENST00000376286	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+	0.000119977	0.99987996
ENST00000376285	ENST00000376387	PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+	0.000377824	0.9996221

Top

Fusion Genomic Features for PCCA-TM9SF2

FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.

Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	1-p	p (fusion gene breakpoint)
PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+	2.23E-05	0.9999777
PCCA	chr13	100809594	+	TM9SF2	chr13	100169867	+	2.23E-05	0.9999777

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.

Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.

Top

Fusion Protein Features for PCCA-TM9SF2

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:100809594/chr13:100169867)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
.	.
FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.	FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page

* Minus value of BPloci means that the break pointn is located before the CDS.

- In-frame and retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

322_374

664.0

Topological domain

Cytoplasmic

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

396_398

664.0

Topological domain

Lumenal

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

420_437

664.0

Topological domain

Cytoplasmic

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

459_466

664.0

Topological domain

Lumenal

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

488_522

664.0

Topological domain

Cytoplasmic

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

544_554

664.0

Topological domain

Lumenal

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

576_591

664.0

Topological domain

Cytoplasmic

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

613_631

664.0

Topological domain

Lumenal

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

653_663

664.0

Topological domain

Cytoplasmic

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

301_321

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

375_395

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

399_419

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

438_458

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

467_487

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

523_543

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

555_575

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

592_612

664.0

Transmembrane

Helical

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

632_652

664.0

Transmembrane

Helical

- In-frame and not-retained protein feature among the 13 regional features.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376279

181_378

156

682.0

Domain

ATP-grasp

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376279

62_509

156

682.0

Domain

Biotin carboxylation

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376279

653_728

156

682.0

Domain

Biotinyl-binding

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376285

181_378

156

729.0

Domain

ATP-grasp

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376285

62_509

156

729.0

Domain

Biotin carboxylation

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376285

653_728

156

729.0

Domain

Biotinyl-binding

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376286

181_378

130

703.0

Domain

ATP-grasp

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376286

62_509

130

703.0

Domain

Biotin carboxylation

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376286

653_728

130

703.0

Domain

Biotinyl-binding

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376279

209_270

156

682.0

Nucleotide binding

ATP

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376285

209_270

156

729.0

Nucleotide binding

ATP

Hgene

PCCA

chr13:100809594

chr13:100169867

ENST00000376286

209_270

130

703.0

Nucleotide binding

ATP

Tgene

TM9SF2

chr13:100809594

chr13:100169867

ENST00000376387

29_300

664.0

Topological domain

Lumenal

Top

Fusion Gene Sequence for PCCA-TM9SF2

For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>63163_63163_1_PCCA-TM9SF2_PCCA_chr13_100809594_ENST00000376279_TM9SF2_chr13_100169867_ENST00000376387_length(transcript)=3643nt_BP=574nt
GGCATCGGGTTTCTGGCTCGTGATTTGCCGGAGCTCCTGCGCTCCCCTTCTCCACCCCCTCCGGCTGTGTGAGAGGTCAGCAGAGGGGCG
GTCTGCGGGGACAACAATGGCGGGGTTCTGGGTCGGGACAGCACCGCTGGTCGCTGCCGGACGGCGTGGGCGGTGGCCGCCGCAGCAGCT
GATGCTGAGCGCGGCGCTGCGGACCCTGAAGCATGTTCTGTACTATTCAAGACAGTGCTTAATGGTGTCCCGTAATCTTGGTTCAGTGGG
ATATGATCCTAATGAAAAAACTTTTGATAAAATTCTTGTTGCTAATAGAGGAGAAATTGCATGTCGGGTTATTAGAACTTGCAAGAAGAT
GGGCATTAAGACAGTTGCCATCCACAGTGATGTTGATGCTAGTTCTGTTCATGTGAAAATGGCGGATGAGGCTGTCTGTGTTGGCCCAGC
TCCCACCAGTAAAAGCTACCTCAACATGGATGCCATCATGGAAGCCATTAAGAAAACCAGGGCCCAAGCTGTACATCCAGGTTATGGATT
CCTTTCAGAAAACAAAGAATTTGCCAGATGTTTGGCCGAAATAGAACTATTTGTGAACAGACTTGATTCAGTGGAATCAGTTCTTCCTTA
TGAATACACAGCGTTTGATTTTTGCCAAGCATCAGAAGGAAAGCGCCCATCTGAAAATCTTGGTCAGGTACTATTCGGGGAAAGAATTGA
ACCTTCACCATATAAGTTTACGTTTAATAAGAAGGAGACCTGTAAGCTTGTTTGTACAAAAACATACCATACAGAGAAAGCTGAAGACAA
ACAAAAGTTAGAATTCTTGAAAAAAAGCATGTTATTGAATTATCAACATCACTGGATTGTGGATAATATGCCTGTAACGTGGTGTTACGA
TGTTGAAGATGGTCAGAGGTTCTGTAATCCTGGATTTCCTATTGGCTGTTACATTACAGATAAAGGCCATGCAAAAGATGCCTGTGTTAT
TAGTTCAGATTTCCATGAAAGAGATACATTTTACATCTTCAACCATGTTGACATCAAAATATACTATCATGTTGTTGAAACTGGGTCCAT
GGGAGCAAGATTAGTGGCTGCTAAACTTGAACCGAAAAGCTTCAAACATACCCATATAGATAAACCAGACTGCTCAGGGCCCCCCATGGA
CATAAGTAACAAGGCTTCTGGGGAGATAAAAATTGCCTATACTTACTCTGTTAGCTTCGAGGAAGATGATAAGATCAGATGGGCGTCTAG
ATGGGACTATATTCTGGAGTCTATGCCTCATACCCACATTCAGTGGTTTAGCATTATGAATTCCCTGGTCATTGTTCTCTTCTTATCTGG
AATGGTAGCTATGATTATGTTACGGACACTGCACAAAGATATTGCTAGATATAATCAGATGGACTCTACGGAAGATGCCCAGGAAGAATT
TGGCTGGAAACTTGTTCATGGTGATATATTCCGTCCTCCAAGAAAAGGGATGCTGCTATCAGTCTTTCTAGGATCCGGGACACAGATTTT
AATTATGACCTTTGTGACTCTATTTTTCGCTTGCCTGGGATTTTTGTCACCTGCCAACCGAGGAGCGCTGATGACGTGTGCTGTGGTCCT
GTGGGTGCTGCTGGGCACCCCTGCAGGCTATGTTGCTGCCAGATTCTATAAGTCCTTTGGAGGTGAGAAGTGGAAAACAAATGTTTTATT
AACATCATTTCTTTGTCCTGGGATTGTATTTGCTGACTTCTTTATAATGAATCTGATCCTCTGGGGAGAAGGATCTTCAGCAGCTATTCC
TTTTGGGACACTGGTTGCCATATTGGCCCTTTGGTTCTGCATATCTGTGCCTCTGACGTTTATTGGTGCATACTTTGGTTTTAAGAAGAA
TGCCATTGAACACCCAGTTCGAACCAATCAGATTCCACGTCAGATTCCTGAACAGTCGTTCTACACGAAGCCCTTGCCTGGTATTATCAT
GGGAGGGATTTTGCCCTTTGGCTGCATCTTTATACAACTTTTCTTCATTCTGAATAGTATTTGGTCACACCAGATGTATTACATGTTTGG
CTTCCTATTTCTGGTGTTTATCATTTTGGTTATTACCTGTTCTGAAGCAACTATACTTCTTTGCTATTTCCACCTATGTGCAGAGGATTA
TCATTGGCAATGGCGTTCATTCCTTACGAGTGGCTTTACTGCAGTTTATTTCTTAATCTATGCAGTACACTACTTCTTTTCAAAACTGCA
GATCACGGGAACAGCAAGCACAATTCTGTACTTTGGTTATACCATGATAATGGTTTTGATCTTCTTTCTTTTTACAGGAACAATTGGCTT
CTTTGCATGCTTTTGGTTTGTTACCAAAATATACAGTGTGGTGAAGGTTGACTGAAGAAGTCCAGTGTGTCCAGTTAAAACAGAAATAAA
TTAAACTCTTCATCAACAAAGACCTGTTTTTGTGACTGCCTTGAGTTTTATCAGAATTATTGGCCTAGTAATCCTTCAGAAACACCGTAA
TTCTAAATAAACCTCTTCCCATACACCTTTCCCCCATAAGATGTGTCTTCAACACTATAAAGCATTTGTATTGTGATTTGATTAAGTATA
TATTTGGTTGTTCTCAATGAAGAGCAAATTTAAATATTATGTGCATTTGTAAATACAGTAGCTATAAAATTTTCCATACTTCTAATGGCA
GAATAGAGGAGGCCATATTAAATAATACTGATGAAAGGCAGGACACTGCATTGTAAATAGGATTTTCTAGGCTCGGTAGGCAGAAAGAAT
TATTTTTCTTTGAAGGAAATAACTTTTTATCATGGTAATTTTGAAGGATGATTCCTATGATGTGTTCACCAGGGGAATGTGGCTTTTAAA
GAAAATCTTCTATTGGTTGTAACTGTTCATATCTTCTTACTTTTCTGTGTTGACTTCATTATTCCCATGGTATTGGCCTTTTAAACTATG
TGCCTCTGAGTCTTTCAATTTATAAATTTGTTATCTTAATAAATATTATAAAAATGTCTTCATTGCATCATTACCTATTATATATTCAAG
GAGGTTCTGTAAATACAGATCTATTTACCAAGGTGTTTTGAAATGATTTATACTATTTTATCAGATTTTACTGGATTTTGTTAATGTAAC
ACTTTCTGAGTTTTGATCTGAATGGAATTTCACTGTGTAAGGCATTGTCTAAAATGTTCACTGTGAGGCAGTAGAGGAGGTTGAAGTCAT
GCATATCTAGACAGATGAATTATCTGCAAGTACTTAAGGTGGAGCCTTACTACATTGTCATTAAGGAGTTTCTATTTTTGACTTGTTTTT
CAAAATACAGTGTTTTAAGTCAGGTTTTATTACCTGGACATTAGCAATCACTAGCAAGTCTTCATCTTTATGATTTCATTGTTTTAATTT
AGATTTCACAAACAGTTTTACTTCTAAGAGTTAAGAAATGCACTGTCTTTCACATTCATCTGACTAATTGAAATCCATTTATGTAGAATA
TAGGAATGGGGGGTGATTCTGAAGTATCGGTCTGCTTGTATCTGTGAGCATATTCATTTGTATTTTAGGGTCTCTCTGCTTGCTGCTTAG

>63163_63163_1_PCCA-TM9SF2_PCCA_chr13_100809594_ENST00000376279_TM9SF2_chr13_100169867_ENST00000376387_length(amino acids)=776AA_BP=170
MCERSAEGRSAGTTMAGFWVGTAPLVAAGRRGRWPPQQLMLSAALRTLKHVLYYSRQCLMVSRNLGSVGYDPNEKTFDKILVANRGEIAC
RVIRTCKKMGIKTVAIHSDVDASSVHVKMADEAVCVGPAPTSKSYLNMDAIMEAIKKTRAQAVHPGYGFLSENKEFARCLAEIELFVNRL
DSVESVLPYEYTAFDFCQASEGKRPSENLGQVLFGERIEPSPYKFTFNKKETCKLVCTKTYHTEKAEDKQKLEFLKKSMLLNYQHHWIVD
NMPVTWCYDVEDGQRFCNPGFPIGCYITDKGHAKDACVISSDFHERDTFYIFNHVDIKIYYHVVETGSMGARLVAAKLEPKSFKHTHIDK
PDCSGPPMDISNKASGEIKIAYTYSVSFEEDDKIRWASRWDYILESMPHTHIQWFSIMNSLVIVLFLSGMVAMIMLRTLHKDIARYNQMD
STEDAQEEFGWKLVHGDIFRPPRKGMLLSVFLGSGTQILIMTFVTLFFACLGFLSPANRGALMTCAVVLWVLLGTPAGYVAARFYKSFGG
EKWKTNVLLTSFLCPGIVFADFFIMNLILWGEGSSAAIPFGTLVAILALWFCISVPLTFIGAYFGFKKNAIEHPVRTNQIPRQIPEQSFY
TKPLPGIIMGGILPFGCIFIQLFFILNSIWSHQMYYMFGFLFLVFIILVITCSEATILLCYFHLCAEDYHWQWRSFLTSGFTAVYFLIYA

--------------------------------------------------------------
>63163_63163_2_PCCA-TM9SF2_PCCA_chr13_100809594_ENST00000376285_TM9SF2_chr13_100169867_ENST00000376387_length(transcript)=3575nt_BP=506nt
GTGAGAGGTCAGCAGAGGGGCGGTCTGCGGGGACAACAATGGCGGGGTTCTGGGTCGGGACAGCACCGCTGGTCGCTGCCGGACGGCGTG
GGCGGTGGCCGCCGCAGCAGCTGATGCTGAGCGCGGCGCTGCGGACCCTGAAGCATGTTCTGTACTATTCAAGACAGTGCTTAATGGTGT
CCCGTAATCTTGGTTCAGTGGGATATGATCCTAATGAAAAAACTTTTGATAAAATTCTTGTTGCTAATAGAGGAGAAATTGCATGTCGGG
TTATTAGAACTTGCAAGAAGATGGGCATTAAGACAGTTGCCATCCACAGTGATGTTGATGCTAGTTCTGTTCATGTGAAAATGGCGGATG
AGGCTGTCTGTGTTGGCCCAGCTCCCACCAGTAAAAGCTACCTCAACATGGATGCCATCATGGAAGCCATTAAGAAAACCAGGGCCCAAG
CTGTACATCCAGGTTATGGATTCCTTTCAGAAAACAAAGAATTTGCCAGATGTTTGGCCGAAATAGAACTATTTGTGAACAGACTTGATT
CAGTGGAATCAGTTCTTCCTTATGAATACACAGCGTTTGATTTTTGCCAAGCATCAGAAGGAAAGCGCCCATCTGAAAATCTTGGTCAGG
TACTATTCGGGGAAAGAATTGAACCTTCACCATATAAGTTTACGTTTAATAAGAAGGAGACCTGTAAGCTTGTTTGTACAAAAACATACC
ATACAGAGAAAGCTGAAGACAAACAAAAGTTAGAATTCTTGAAAAAAAGCATGTTATTGAATTATCAACATCACTGGATTGTGGATAATA
TGCCTGTAACGTGGTGTTACGATGTTGAAGATGGTCAGAGGTTCTGTAATCCTGGATTTCCTATTGGCTGTTACATTACAGATAAAGGCC
ATGCAAAAGATGCCTGTGTTATTAGTTCAGATTTCCATGAAAGAGATACATTTTACATCTTCAACCATGTTGACATCAAAATATACTATC
ATGTTGTTGAAACTGGGTCCATGGGAGCAAGATTAGTGGCTGCTAAACTTGAACCGAAAAGCTTCAAACATACCCATATAGATAAACCAG
ACTGCTCAGGGCCCCCCATGGACATAAGTAACAAGGCTTCTGGGGAGATAAAAATTGCCTATACTTACTCTGTTAGCTTCGAGGAAGATG
ATAAGATCAGATGGGCGTCTAGATGGGACTATATTCTGGAGTCTATGCCTCATACCCACATTCAGTGGTTTAGCATTATGAATTCCCTGG
TCATTGTTCTCTTCTTATCTGGAATGGTAGCTATGATTATGTTACGGACACTGCACAAAGATATTGCTAGATATAATCAGATGGACTCTA
CGGAAGATGCCCAGGAAGAATTTGGCTGGAAACTTGTTCATGGTGATATATTCCGTCCTCCAAGAAAAGGGATGCTGCTATCAGTCTTTC
TAGGATCCGGGACACAGATTTTAATTATGACCTTTGTGACTCTATTTTTCGCTTGCCTGGGATTTTTGTCACCTGCCAACCGAGGAGCGC
TGATGACGTGTGCTGTGGTCCTGTGGGTGCTGCTGGGCACCCCTGCAGGCTATGTTGCTGCCAGATTCTATAAGTCCTTTGGAGGTGAGA
AGTGGAAAACAAATGTTTTATTAACATCATTTCTTTGTCCTGGGATTGTATTTGCTGACTTCTTTATAATGAATCTGATCCTCTGGGGAG
AAGGATCTTCAGCAGCTATTCCTTTTGGGACACTGGTTGCCATATTGGCCCTTTGGTTCTGCATATCTGTGCCTCTGACGTTTATTGGTG
CATACTTTGGTTTTAAGAAGAATGCCATTGAACACCCAGTTCGAACCAATCAGATTCCACGTCAGATTCCTGAACAGTCGTTCTACACGA
AGCCCTTGCCTGGTATTATCATGGGAGGGATTTTGCCCTTTGGCTGCATCTTTATACAACTTTTCTTCATTCTGAATAGTATTTGGTCAC
ACCAGATGTATTACATGTTTGGCTTCCTATTTCTGGTGTTTATCATTTTGGTTATTACCTGTTCTGAAGCAACTATACTTCTTTGCTATT
TCCACCTATGTGCAGAGGATTATCATTGGCAATGGCGTTCATTCCTTACGAGTGGCTTTACTGCAGTTTATTTCTTAATCTATGCAGTAC
ACTACTTCTTTTCAAAACTGCAGATCACGGGAACAGCAAGCACAATTCTGTACTTTGGTTATACCATGATAATGGTTTTGATCTTCTTTC
TTTTTACAGGAACAATTGGCTTCTTTGCATGCTTTTGGTTTGTTACCAAAATATACAGTGTGGTGAAGGTTGACTGAAGAAGTCCAGTGT
GTCCAGTTAAAACAGAAATAAATTAAACTCTTCATCAACAAAGACCTGTTTTTGTGACTGCCTTGAGTTTTATCAGAATTATTGGCCTAG
TAATCCTTCAGAAACACCGTAATTCTAAATAAACCTCTTCCCATACACCTTTCCCCCATAAGATGTGTCTTCAACACTATAAAGCATTTG
TATTGTGATTTGATTAAGTATATATTTGGTTGTTCTCAATGAAGAGCAAATTTAAATATTATGTGCATTTGTAAATACAGTAGCTATAAA
ATTTTCCATACTTCTAATGGCAGAATAGAGGAGGCCATATTAAATAATACTGATGAAAGGCAGGACACTGCATTGTAAATAGGATTTTCT
AGGCTCGGTAGGCAGAAAGAATTATTTTTCTTTGAAGGAAATAACTTTTTATCATGGTAATTTTGAAGGATGATTCCTATGATGTGTTCA
CCAGGGGAATGTGGCTTTTAAAGAAAATCTTCTATTGGTTGTAACTGTTCATATCTTCTTACTTTTCTGTGTTGACTTCATTATTCCCAT
GGTATTGGCCTTTTAAACTATGTGCCTCTGAGTCTTTCAATTTATAAATTTGTTATCTTAATAAATATTATAAAAATGTCTTCATTGCAT
CATTACCTATTATATATTCAAGGAGGTTCTGTAAATACAGATCTATTTACCAAGGTGTTTTGAAATGATTTATACTATTTTATCAGATTT
TACTGGATTTTGTTAATGTAACACTTTCTGAGTTTTGATCTGAATGGAATTTCACTGTGTAAGGCATTGTCTAAAATGTTCACTGTGAGG
CAGTAGAGGAGGTTGAAGTCATGCATATCTAGACAGATGAATTATCTGCAAGTACTTAAGGTGGAGCCTTACTACATTGTCATTAAGGAG
TTTCTATTTTTGACTTGTTTTTCAAAATACAGTGTTTTAAGTCAGGTTTTATTACCTGGACATTAGCAATCACTAGCAAGTCTTCATCTT
TATGATTTCATTGTTTTAATTTAGATTTCACAAACAGTTTTACTTCTAAGAGTTAAGAAATGCACTGTCTTTCACATTCATCTGACTAAT
TGAAATCCATTTATGTAGAATATAGGAATGGGGGGTGATTCTGAAGTATCGGTCTGCTTGTATCTGTGAGCATATTCATTTGTATTTTAG

>63163_63163_2_PCCA-TM9SF2_PCCA_chr13_100809594_ENST00000376285_TM9SF2_chr13_100169867_ENST00000376387_length(amino acids)=762AA_BP=156
MAGFWVGTAPLVAAGRRGRWPPQQLMLSAALRTLKHVLYYSRQCLMVSRNLGSVGYDPNEKTFDKILVANRGEIACRVIRTCKKMGIKTV
AIHSDVDASSVHVKMADEAVCVGPAPTSKSYLNMDAIMEAIKKTRAQAVHPGYGFLSENKEFARCLAEIELFVNRLDSVESVLPYEYTAF
DFCQASEGKRPSENLGQVLFGERIEPSPYKFTFNKKETCKLVCTKTYHTEKAEDKQKLEFLKKSMLLNYQHHWIVDNMPVTWCYDVEDGQ
RFCNPGFPIGCYITDKGHAKDACVISSDFHERDTFYIFNHVDIKIYYHVVETGSMGARLVAAKLEPKSFKHTHIDKPDCSGPPMDISNKA
SGEIKIAYTYSVSFEEDDKIRWASRWDYILESMPHTHIQWFSIMNSLVIVLFLSGMVAMIMLRTLHKDIARYNQMDSTEDAQEEFGWKLV
HGDIFRPPRKGMLLSVFLGSGTQILIMTFVTLFFACLGFLSPANRGALMTCAVVLWVLLGTPAGYVAARFYKSFGGEKWKTNVLLTSFLC
PGIVFADFFIMNLILWGEGSSAAIPFGTLVAILALWFCISVPLTFIGAYFGFKKNAIEHPVRTNQIPRQIPEQSFYTKPLPGIIMGGILP
FGCIFIQLFFILNSIWSHQMYYMFGFLFLVFIILVITCSEATILLCYFHLCAEDYHWQWRSFLTSGFTAVYFLIYAVHYFFSKLQITGTA

--------------------------------------------------------------
>63163_63163_3_PCCA-TM9SF2_PCCA_chr13_100809594_ENST00000376286_TM9SF2_chr13_100169867_ENST00000376387_length(transcript)=3565nt_BP=496nt
GGCATCGGGTTTCTGGCTCGTGATTTGCCGGAGCTCCTGCGCTCCCCTTCTCCACCCCCTCCGGCTGTGTGAGAGGTCAGCAGAGGGGCG
GTCTGCGGGGACAACAATGGCGGGGTTCTGGGTCGGGACAGCACCGCTGGTCGCTGCCGGACGGCGTGGGCGGTGGCCGCCGCAGCAGCT
GATGCTGAGCGCGGCGCTGCGGACCCTGAAGACTTTTGATAAAATTCTTGTTGCTAATAGAGGAGAAATTGCATGTCGGGTTATTAGAAC
TTGCAAGAAGATGGGCATTAAGACAGTTGCCATCCACAGTGATGTTGATGCTAGTTCTGTTCATGTGAAAATGGCGGATGAGGCTGTCTG
TGTTGGCCCAGCTCCCACCAGTAAAAGCTACCTCAACATGGATGCCATCATGGAAGCCATTAAGAAAACCAGGGCCCAAGCTGTACATCC
AGGTTATGGATTCCTTTCAGAAAACAAAGAATTTGCCAGATGTTTGGCCGAAATAGAACTATTTGTGAACAGACTTGATTCAGTGGAATC
AGTTCTTCCTTATGAATACACAGCGTTTGATTTTTGCCAAGCATCAGAAGGAAAGCGCCCATCTGAAAATCTTGGTCAGGTACTATTCGG
GGAAAGAATTGAACCTTCACCATATAAGTTTACGTTTAATAAGAAGGAGACCTGTAAGCTTGTTTGTACAAAAACATACCATACAGAGAA
AGCTGAAGACAAACAAAAGTTAGAATTCTTGAAAAAAAGCATGTTATTGAATTATCAACATCACTGGATTGTGGATAATATGCCTGTAAC
GTGGTGTTACGATGTTGAAGATGGTCAGAGGTTCTGTAATCCTGGATTTCCTATTGGCTGTTACATTACAGATAAAGGCCATGCAAAAGA
TGCCTGTGTTATTAGTTCAGATTTCCATGAAAGAGATACATTTTACATCTTCAACCATGTTGACATCAAAATATACTATCATGTTGTTGA
AACTGGGTCCATGGGAGCAAGATTAGTGGCTGCTAAACTTGAACCGAAAAGCTTCAAACATACCCATATAGATAAACCAGACTGCTCAGG
GCCCCCCATGGACATAAGTAACAAGGCTTCTGGGGAGATAAAAATTGCCTATACTTACTCTGTTAGCTTCGAGGAAGATGATAAGATCAG
ATGGGCGTCTAGATGGGACTATATTCTGGAGTCTATGCCTCATACCCACATTCAGTGGTTTAGCATTATGAATTCCCTGGTCATTGTTCT
CTTCTTATCTGGAATGGTAGCTATGATTATGTTACGGACACTGCACAAAGATATTGCTAGATATAATCAGATGGACTCTACGGAAGATGC
CCAGGAAGAATTTGGCTGGAAACTTGTTCATGGTGATATATTCCGTCCTCCAAGAAAAGGGATGCTGCTATCAGTCTTTCTAGGATCCGG
GACACAGATTTTAATTATGACCTTTGTGACTCTATTTTTCGCTTGCCTGGGATTTTTGTCACCTGCCAACCGAGGAGCGCTGATGACGTG
TGCTGTGGTCCTGTGGGTGCTGCTGGGCACCCCTGCAGGCTATGTTGCTGCCAGATTCTATAAGTCCTTTGGAGGTGAGAAGTGGAAAAC
AAATGTTTTATTAACATCATTTCTTTGTCCTGGGATTGTATTTGCTGACTTCTTTATAATGAATCTGATCCTCTGGGGAGAAGGATCTTC
AGCAGCTATTCCTTTTGGGACACTGGTTGCCATATTGGCCCTTTGGTTCTGCATATCTGTGCCTCTGACGTTTATTGGTGCATACTTTGG
TTTTAAGAAGAATGCCATTGAACACCCAGTTCGAACCAATCAGATTCCACGTCAGATTCCTGAACAGTCGTTCTACACGAAGCCCTTGCC
TGGTATTATCATGGGAGGGATTTTGCCCTTTGGCTGCATCTTTATACAACTTTTCTTCATTCTGAATAGTATTTGGTCACACCAGATGTA
TTACATGTTTGGCTTCCTATTTCTGGTGTTTATCATTTTGGTTATTACCTGTTCTGAAGCAACTATACTTCTTTGCTATTTCCACCTATG
TGCAGAGGATTATCATTGGCAATGGCGTTCATTCCTTACGAGTGGCTTTACTGCAGTTTATTTCTTAATCTATGCAGTACACTACTTCTT
TTCAAAACTGCAGATCACGGGAACAGCAAGCACAATTCTGTACTTTGGTTATACCATGATAATGGTTTTGATCTTCTTTCTTTTTACAGG
AACAATTGGCTTCTTTGCATGCTTTTGGTTTGTTACCAAAATATACAGTGTGGTGAAGGTTGACTGAAGAAGTCCAGTGTGTCCAGTTAA
AACAGAAATAAATTAAACTCTTCATCAACAAAGACCTGTTTTTGTGACTGCCTTGAGTTTTATCAGAATTATTGGCCTAGTAATCCTTCA
GAAACACCGTAATTCTAAATAAACCTCTTCCCATACACCTTTCCCCCATAAGATGTGTCTTCAACACTATAAAGCATTTGTATTGTGATT
TGATTAAGTATATATTTGGTTGTTCTCAATGAAGAGCAAATTTAAATATTATGTGCATTTGTAAATACAGTAGCTATAAAATTTTCCATA
CTTCTAATGGCAGAATAGAGGAGGCCATATTAAATAATACTGATGAAAGGCAGGACACTGCATTGTAAATAGGATTTTCTAGGCTCGGTA
GGCAGAAAGAATTATTTTTCTTTGAAGGAAATAACTTTTTATCATGGTAATTTTGAAGGATGATTCCTATGATGTGTTCACCAGGGGAAT
GTGGCTTTTAAAGAAAATCTTCTATTGGTTGTAACTGTTCATATCTTCTTACTTTTCTGTGTTGACTTCATTATTCCCATGGTATTGGCC
TTTTAAACTATGTGCCTCTGAGTCTTTCAATTTATAAATTTGTTATCTTAATAAATATTATAAAAATGTCTTCATTGCATCATTACCTAT
TATATATTCAAGGAGGTTCTGTAAATACAGATCTATTTACCAAGGTGTTTTGAAATGATTTATACTATTTTATCAGATTTTACTGGATTT
TGTTAATGTAACACTTTCTGAGTTTTGATCTGAATGGAATTTCACTGTGTAAGGCATTGTCTAAAATGTTCACTGTGAGGCAGTAGAGGA
GGTTGAAGTCATGCATATCTAGACAGATGAATTATCTGCAAGTACTTAAGGTGGAGCCTTACTACATTGTCATTAAGGAGTTTCTATTTT
TGACTTGTTTTTCAAAATACAGTGTTTTAAGTCAGGTTTTATTACCTGGACATTAGCAATCACTAGCAAGTCTTCATCTTTATGATTTCA
TTGTTTTAATTTAGATTTCACAAACAGTTTTACTTCTAAGAGTTAAGAAATGCACTGTCTTTCACATTCATCTGACTAATTGAAATCCAT
TTATGTAGAATATAGGAATGGGGGGTGATTCTGAAGTATCGGTCTGCTTGTATCTGTGAGCATATTCATTTGTATTTTAGGGTCTCTCTG

>63163_63163_3_PCCA-TM9SF2_PCCA_chr13_100809594_ENST00000376286_TM9SF2_chr13_100169867_ENST00000376387_length(amino acids)=750AA_BP=144
MCERSAEGRSAGTTMAGFWVGTAPLVAAGRRGRWPPQQLMLSAALRTLKTFDKILVANRGEIACRVIRTCKKMGIKTVAIHSDVDASSVH
VKMADEAVCVGPAPTSKSYLNMDAIMEAIKKTRAQAVHPGYGFLSENKEFARCLAEIELFVNRLDSVESVLPYEYTAFDFCQASEGKRPS
ENLGQVLFGERIEPSPYKFTFNKKETCKLVCTKTYHTEKAEDKQKLEFLKKSMLLNYQHHWIVDNMPVTWCYDVEDGQRFCNPGFPIGCY
ITDKGHAKDACVISSDFHERDTFYIFNHVDIKIYYHVVETGSMGARLVAAKLEPKSFKHTHIDKPDCSGPPMDISNKASGEIKIAYTYSV
SFEEDDKIRWASRWDYILESMPHTHIQWFSIMNSLVIVLFLSGMVAMIMLRTLHKDIARYNQMDSTEDAQEEFGWKLVHGDIFRPPRKGM
LLSVFLGSGTQILIMTFVTLFFACLGFLSPANRGALMTCAVVLWVLLGTPAGYVAARFYKSFGGEKWKTNVLLTSFLCPGIVFADFFIMN
LILWGEGSSAAIPFGTLVAILALWFCISVPLTFIGAYFGFKKNAIEHPVRTNQIPRQIPEQSFYTKPLPGIIMGGILPFGCIFIQLFFIL
NSIWSHQMYYMFGFLFLVFIILVITCSEATILLCYFHLCAEDYHWQWRSFLTSGFTAVYFLIYAVHYFFSKLQITGTASTILYFGYTMIM

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for PCCA-TM9SF2

Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in
ChiPPI page.

Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)

Hgene

Hgene's interactors

Tgene

Tgene's interactors

- Retained PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Still interaction with

- Lost PPIs in in-frame fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

- Retained PPIs, but lost function due to frame-shift fusion.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Interaction lost with

Top

Related Drugs for PCCA-TM9SF2

Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)

Partner

Gene

UniProtAcc

DrugBank ID

Drug name

Drug activity

Drug type

Drug status

Top

Related Diseases for PCCA-TM9SF2

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source